Effects of Biochanin A on Resistin, Adiponectin and some stress oxidative markers in normal and STZ- Induced Diabetic Rats
Archives of Medical Laboratory Sciences,
Vol. 4 No. 2 (2018),
13 October 2019
,
Page 9-16
https://doi.org/10.22037/amls.v4i2.24908
Abstract
Background: Elevated serum level of adiponectin and insulin and decreased serum resistin can improve glucose metabolism. Biochanin A (BCA) is a flavonoid of Soybean that shows antioxidant properties. This study was aimed to examine the effect of BCA on FBS, oxidative stress and serum levels of adiponectin, resistin and insulin in rats with type 1 diabetes.
Material and method: The rats were randomly divided into five groups (n=6). BCA was administered orally in doses of 10 and 15 mg/kg of body weight. Insulin, resistin and adiponectin were measured using ELISA kits. The activity of Gamma-Glutamyltransferase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and the levels of Glutathione (GSH) were examined.
Results: The results showed that BCA treatment significantly reduced the FBS level in diabetic rats (p<0.05). Serum insulin was significantly increased in the BCA treated diabetic rats (p<0.05). Moreover, GGT activity and GSH was significantly increased in treated rats (p<0.05). Our findings revealed that the administration of BCA significantly increased the serum adiponectin (p<0.05). Additionally, serum resistin levels were remarkably decreased in treated rats (p<0.05).
Conclusion: Taken together, BCA represents a natural phytoestrogen that has an important role in improvement of glucose metabolism by regulating of adipokines secretion; also our findings revealed the beneficial effects of BCA against oxidative stress in diabetes
- Adiponectin
- Biochanin A
- Oxidative stress
- Resistin
- Type 1 diabetes
How to Cite
References
Kerner W, Brückel J. Definition: classification and diagnosis of diabetes mellitus. Exp Clin Endocr Diab. 2014;122(07):384-6.
Dafoulas GE, Toulis KA, Mccorry D: Type 1 diabetes mellitus and risk of incident epilepsy: a population- based, open-cohort study. Diabetologia. 2017;60(2):258-61.
Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. The Lancet. 2014;383(9911):69-82.
Coleman SK, Rebalka IA, D’Souza DM: Skeletal muscle as a therapeutic target for delaying type 1 diabetic complications. World journal of diabetes. 2015;6(17):1323.
Vanessa Fiorentino T, Prioletta A, Zuo P: Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Design. 2013;19(32):5695-703.
Cleland S, Fisher B, Colhoun H: Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? Diabetologia. 2013;56(7):1462-70.
Jassam N, Amin N, Holland P: Analytical and clinical challenges in a patient with concurrent type 1 diabetes, subcutaneous insulin resistance and insulin autoimmune syndrome. Endocrinology, diabetes & metabolism case reports. 2014;2014.
Halberg N, Wernstedt-Asterholm I, Scherer PE: The adipocyte as an endocrine cell. Endocrinology and Metabolism Clinics. 2008;37(3):753-68.
Coelho M, Oliveira T, Fernandes R: Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013; 9 (2): 191–200. 2013.
Yamauchi T, Iwabu M, Okada-Iwabu M: Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Cl En. 2014;28(1):15-23.
Steppan CM, Bailey ST, Bhat S: The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307.
Furukawa S, Fujita T, Shimabukuro M: Increased oxidative stress in obesity and its impact on metabolic syndrome. The Journal of clinical investigation. 2017;114(12):1752-61.
Karp DR, Shimooku K, Lipsky PE: Expression of γ-glutamyl transpeptidase protects ramos B cells from oxidation-induced cell death. J Biol Chem. 2001;276(6):3798-804.
Babu PVA, Liu D, Gilbert ER: Recent advances in understanding the anti-diabetic actions of dietary flavonoids. The Journal of nutritional biochemistry. 2013;24(11):1777-89.
Sadri H, Goodarzi MT, Salemi Z: Antioxidant Effects of Biochanin A in Streptozotocin Induced Diabetic Rats. Braz Arch Biol Techn. 2017;60.
Jalaludeen AM, Lee WY, Kim JH: Therapeutic efficacy of biochanin a against arsenic-induced renal and cardiac damage in rats. Environ Toxicol Phar. 2015;39(3):1221-31.
Thiraphatthanavong P, Wattanathorn J, Muchimapura S: The combined extract of purple waxy corn and ginger prevents cataractogenesis and retinopathy in streptozotocin-diabetic rats. Oxidative medicine and cellular longevity. 2014;2014.
Lee G, Goosens KA: Sampling blood from the lateral tail vein of the rat. Journal of visualized experiments: JoVE. 2015(99).
Salemi Z, Barzin ST, Fallah S: The effect of Morus alba leaves extract and powder on resistin levels and liver transaminase enzymes activities in diabetes. Cell Mol Biol (Noisy-le-Grand, France). 2016;62(6):112-8.
Harini R, Ezhumalai M, Pugalendi KV: Antihyperglycemic effect of biochanin A, a soy isoflavone, on streptozotocin-diabetic rats. Eur J Pharmacol. 2012;676(1-3):89-94.
Rajkumar L, Srinivasan N, Balasubramanian K: Increased degradation of dermal collagen in diabetic rats. Indian J Exp Biol.1991;29(11):1081-3.
Pepato MT, Migliorini RH, Goldberg AL: Role of different proteolytic pathways in degradation of muscle protein from streptozotocin-diabetic rats. Am J Physiol-Endoc M. 1996;271(2):E340-E7.
Unnikrishnan M, Veerapur V, Nayak Y: Antidiabetic, antihyperlipidemic and antioxidant effects of the flavonoids. Polyphenols in human health and disease: Elsevier; 2014. p. 143-61.
El-Khateeb AY, Azzaz NA-KE, Mahmoud HI: Phytochemical constituents, hypoglycemic and haematological effects of methanolic Acalypha wilkesiana leaves extract on streptozotocin-induced diabetic rats. European Journal of Chemistry. 2014;5(3):430-8.
Caselli C: Role of adiponectin system in insulin resistance. Mol Genet Metab.2014;113(3):155-60.
Suzuki ST, Zhao B, Yang J: Enhanced muscle by myostatin propeptide increases adipose tissue adiponectin, PPAR-α, and PPAR-γ expressions. Biochem Bioph Res Co.2008;369(2):767-73.
Pita J, Panadero A, Soriano-Guillén L: The insulin sensitizing effects of PPAR-γ agonist are associated to changes in adiponectin index and adiponectin receptors in Zucker fatty rats. Regulatory Peptides. 2012;174(1-3):18- 25.
Ghadimi D, Goodarzi MT, Ziamajidi N: The effect of Biochanin A on the expression of Adiponectin in adipose tissue of Streptozotocin-Nicotinamide induced diabetic rats. International Journal Of Medical Research & Health Sciences. 2016;5(7):223-30.
Asterholm IW, Rutkowski JM, Fujikawa T: Elevated resistin levels induce central leptin resistance and increased atherosclerotic progression in mice. Diabetologia. 2014;57(6):1209-18.
Abate N, S Sallam H, Rizzo M: Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Current pharmaceutical design. 2014;20(31):4961-9.
Santilli F, Liani R, Di Fulvio P: Increased circulating resistin is associated with insulin resistance, oxidative stress and platelet activation in type 2 diabetes mellitus. Thrombosis and haemostasis. 2016;116(6):1089-99.
Maiese K: New insights for oxidative stress and diabetes mellitus. Oxidative Medicine and Cellular Longevity. 2015;2015.
Hanigan MH: Gamma-glutamyl transpeptidase: redox regulation and drug resistance. Advances in cancer research. 122: Elsevier; 2014. p. 103-41.
C Stefani I, Wright D, M Polizzi K: The role of ER stress-induced apoptosis in neurodegeneration. Current Alzheimer Research. 2012;9(3):373-87.
Ravuri C, Svineng G, Huseby N-E: Differential regulation of γ-glutamyltransferase and glutamate cysteine ligase expression after mitochondrial uncoupling: γ-glutamyltransferase is regulated in an Nrf2-and NFκB- independent manner. Free radical research. 2013;47(5):394-403.
Tangvarasittichai S: Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World journal of diabetes. 2015;6(3):456.
Ansley DM, Wang B: Oxidative stress and myocardial injury in the diabetic heart. The Journal of pathology. 2013;229(2):232-41.
Matsuda M, Shimomura I: Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obesity research & clinical practice. 2013;7(5):e330-e41.
Nannipieri M, Gonzales C, Baldi S: Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes care. 2005;28(7):1757-62.
- Abstract Viewed: 328 times
- PDF Downloaded: 228 times